Cited by 1,275Liver Disease Diagnosis and TreatmentUltrasound Imaging and ElastographyUltrasound in Clinical Applications

The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

Open access

Karlas, Thomas, Petroff, David, Sasso, Magali, Fan, Jian-Gao, Mi, Yu-Qiang, de Lédinghen, Victor, Kumar, Manoj, Lupsor-Platon, Monica, Han, Kwang-Hyub, Cardoso, Ana C., Ferraioli, Giovanna, Chan, Wah-Kheong, Wong, Vincent Wai-Sun, Myers, Robert P., Chayama, Kazuaki, Friedrich-Rust, Mireen, Beaugrand, Michel, Shen, Feng, Hiriart, Jean-Baptiste, Sarin, Shiv K., Badea, Radu, Jung, Kyu Sik, Marcellin, Patrick, Filice, Carlo, Mahadeva, Sanjiv, Wong, Grace Lai-Hung, Crotty, Pam, Masaki, Keiichi, Bojunga, Joerg, Bedossa, Pierre, Keim, Volker, Wiegand, Johannes·2017·Journal of Hepatology

DOI 10.1016/j.jhep.2016.12.022

Open this paper in CoChat — free account

Abstract

Background & aims The prevalence of fatty liver underscores the need for non-invasive characterization of steatosis, such as the ultrasound based controlled attenuation parameter (CAP). Despite good diagnostic accuracy, clinical use of CAP is limited due to uncertainty regarding optimal cut-offs and the influence of covariates. We therefore conducted an individual patient data meta-analysis.Methods A review of the literature identified studies containing histology verified CAP data (M probe, vibration controlled transient elastography with FibroScan®) for grading of steatosis (S0-S3). Receiver operating characteristic analysis after correcting for center effects was used as well as mixed models to test the impact of covariates on CAP. The primary outcome was establishing CAP cut-offs for distinguishing steatosis grades.Results Data from 19/21 eligible papers were provided, comprising 3830/3968 (97%) of patients. Considering data overlap and exclusion criteria, 2735 patients were included in the final analysis (37% hepatitis B, 36% hepatitis C, 20% NAFLD/NASH, 7% other). Steatosis distribution was 51%/27%/16%/6% for S0/S1/S2/S3. CAP values in dB/m (95% CI) were influenced by several covariates with an estimated shift of 10 (4.5-17) for NAFLD/NASH patients, 10 (3.5-16) for diabetics and 4.4 (3.8-5.0) per BMI unit. Areas under the curves were 0.823 (0.809-0.837) and 0.865 (0.850-0.880) respectively. Optimal cut-offs were 248 (237-261) and 268 (257-284) for those above S0 and S1 respectively.Conclusions CAP provides a standardized non-invasive measure of hepatic steatosis. Prevalence, etiology, diabetes, and BMI deserve consideration when interpreting CAP. Longitudinal data are needed to demonstrate how CAP relates to clinical outcomes.Lay summary There is an increase in fatty liver for patients with chronic liver disease, linked to the epidemic of the obesity. Invasive liver biopsies are considered the best means of diagnosing fatty liver. The ultrasound based controlled attenuation parameter (CAP) can be used instead, but factors such as the underlying disease, BMI and diabetes must be taken into account. Registration: Prospero CRD42015027238.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2016.12.022

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
Modern Applied Statistics with S
Venables, W. N., & Ripley, B. D. (2002) · Statisctics and computing/Statistics and computing · doi:10.1007/978-0-387-21706-2 · Cited by 25,941
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Fitting Linear Mixed-Effects Models Using lme4Preprint
Bates, D. M., Maechler, M., Bolker, B. M., & Walker, S. (2014) · arXiv (Cornell University) · doi:10.3929/ethz-b-000105397 · Cited by 9,435
Histological grading and staging of chronic hepatitis.
Ishak, K., Baptista, A., Bianchi, L., Callea, F., Groote, J. D., Gudat, F., Denk, H., Desmet, V., Korb, G., Macsween, R. N., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,290
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients With Chronic Hepatitis C
Bédossa, P. (1994) · Hepatology · doi:10.1002/hep.1840200104 · Cited by 2,189
AASLD guidelines for treatment of chronic hepatitis B
Terrault, N. A., Bzowej, N. H., Chang, K., Hwang, J. P., Jonas, M. M., & Murad, M. H. (2015) · Hepatology · doi:10.1002/hep.28156 · Cited by 2,002

Flagged first, then by citations

Show all 65 references

1 of the 65 references couldn’t be matched to a known paper.

Sorted by citations

Items 901–1,000 of 1,000

Parental History of Type 2 Diabetes Mellitus and PNPLA3 Polymorphism Increase the Risk of Severe Stages of Nonalcoholic Fatty Liver Disease
Wajsbrot, N. B., Leite, N. C., de França, P. H. C., Cardoso, C. R. L., Salles, G. F., & Villela‐Nogueira, C. A. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-08214-7 · Cited by 2
Factors associated with pre-treatment hyperferritinemia in patients with chronic hepatitis C virus infection
Chang, Y., Huang, C., Kao, J., Su, T., Huang, S., Tseng, T., Chen, P., Liu, C., & Liu, C. (2024) · Scientific Reports · doi:10.1038/s41598-024-70233-9 · Cited by 2
An Australian Community-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Care Pathway for People with Type 2 Diabetes: Barriers and Considerations
Gracen, L., Aikebuse, M., Sarraf, B., McPhail, S., Russell, A. W., O’Beirne, J. P., Irvine, K. M., Williams, S., Valery, P. C., & Powell, E. E. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s468705 · Cited by 2
Changes in Hepatic Steatosis Before and After Direct-Acting Antiviral Treatment in People With HIV and Hepatitis C Coinfection
Truscello, E., Wang, S., Young, J., Sebastiani, G., Walmsley, S. L., Hull, M., Cooper, C., & Klein, M. B. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae487 · Cited by 2
Association of dietary inflammatory index with sarcopenia in patients with Metabolic dysfunction-associated fatty liver disease: a cross-sectional study
Wang, X., Shi, R., Zi, Y., & Long, J. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1486898 · Cited by 2
Prevalence of cardiometabolic co-morbidities in patients with vs persons without chronic hepatitis B: The FitLiver cohort study
Jespersen, S., Fritt-Rasmussen, A., Madsbad, S., Pedersen, B. K., Krogh‐Madsen, R., & Weis, N. M. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i1.97797 · Cited by 2
A hypocaloric protein-rich diet before metabolic surgery improves liver function in patients with obesity and diabetes
Krönert, N., Moulla, Y., Lange, U. G., Blüher, M., Linder, N., Fuhrmann, A., Busse, H., Linder, A., Karlas, T., Wiegand, J., et al. (2025) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-024-03600-9 · Cited by 2
Self-citation
Association between excessive screen time and steatotic liver disease in adolescents: Findings from the 2017–2018 National Health and Nutrition Examination Survey
Li, S., Jin, S., Fang, P., Pan, C., & Huang, S. (2025) · Pediatric Obesity · doi:10.1111/ijpo.70010 · Cited by 2
Inter- and Intraobserver variability of attenuation coefficient measurement in innovative ultrasound diagnosis of metabolic dysfunction-associated steatotic liver disease: a cross-sectional study
Zhaivoronok, M., Dynnyk, O., Livkutnyk, O., Yerokhovych, V., Yuzvenko, V., Serednia, I., Melnychenko, Y., & Kobyliak, N. M. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1457960 · Cited by 2
Three-dimensional organ segmentation-derived CT attenuation parameters for assessing hepatic steatosis in chronic hepatitis B patients
Yoo, J., Joo, I., Jeon, S. K., Park, J., & Cho, E. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-96053-z · Cited by 2
Association of serum uric acid-to-high-density lipoprotein cholesterol ratio with cardiovascular disease risk in patients with metabolic dysfunction-associated fatty liver disease: a cross-sectional NHANES analysis
Wang, X., Shi, Y., Zi, Y., Long, J., & Shi, R. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1561594 · Cited by 2
An inverted U-shaped association between high-sensitivity C-reactive protein and the albumin ratio and hepatic steatosis and liver fibrosis: a population-based study
Ma, X., Li, B., Liu, Y., & Guo, X. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1534200 · Cited by 2
Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Children with Overweight and Obesity by Transient Elastography
Fajrudheen, M., Mahapatro, S., Panigrahi, M. K., Naik, S., & Satapathy, A. K. (2025) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_150_24 · Cited by 2
Predicting the risk of developing diabetes in steatotic liver disease using controlled attenuation parameter in a health checkup population
Nakatsuka, T., Yamaji, Y., Tateishi, R., Ogasawara, T., Mihara, R., Kawashima, Y., Ono, T., Yamada, T., Minami, T., Sato, M., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14216 · Cited by 2
Performance of a Chest Radiograph–based Deep Learning Model for Detecting Hepatic Steatosis
Ueda, D., Uchida‐Kobayashi, S., Yamamoto, A., Walston, S. L., Motoyama, H., Fujii, H., Watanabe, T., Miki, Y., & Kawada, N. (2025) · Radiology Cardiothoracic Imaging · doi:10.1148/ryct.240402 · Cited by 2
MASLD-related fibrosis, but not MASLD, is associated with left ventricular concentric hypertrophy in patients with type 2 diabetes
Lin, J., Chen, R., Huang, J., Liu, Y., Huang, C., Huang, Y., Xu, B., Li, Y., He, X., Lv, H., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02682-6 · Cited by 2
Paradoxical association between steatotic liver disease and favorable hepatic outcomes in HCV patients with SVRs
Chang, M., Cheng, J., Tai, J., Chen, W.-T., Yang, S.-S., Chiu, C.-H., Chien, R., Hsu, C., Wu, S.-J., & Fann, C. S. J. (2025) · Hepatology International · doi:10.1007/s12072-025-10906-3 · Cited by 2
Network Modeling of Biomarker Systems in Liver Steatosis and Fibrosis
Bhat, A. G., & Ramanathan, M. K. (2025) · Clinical and Translational Science · doi:10.1111/cts.70352 · Cited by 2
A model for predicting high BMI of people living with HIV after receiving antiretroviral therapy
Qian, Z., Wu, H., Wu, Y., Liao, W., Yu, T., Xu, X., Peng, J., & Cai, S. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221102750 · Cited by 2
Liver Fibrosis Assessment in Adults with Alpha1-Antitrypsin Deficiency
Pereira, V. M., Hamesch, K., & Strnad, P. (2020) · Springer eBooks · doi:10.1007/978-3-030-40542-7_17 · Cited by 2
Nonalcoholic Fatty Liver Disease and Obesity
De, A., & Duseja, A. K. (2021) · Journal of Postgraduate Medicine Education and Research · doi:10.5005/jp-journals-10028-1430 · Cited by 2
Fatty Acid-Binding Protein 1 as a Potential New Serological Marker of Liver Status in Children With Wilson Disease
Bierła, J. B., Jańczyk, W., Konopka, E., Wierzbicka, A., Więckowski, S., Obrycki, Ł., Sarnecki, J., Kanarek, E., Cukrowská, B., & Socha, P. (2021) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003128 · Cited by 2
Possibilities of ultrasonic methods of research in the diagnosis of non-alcoholic fat liver disease in children
Dykan, I. M., Korobko, V. B., Березенко, В. С., Tarasyuk, B. A., Solodushchenko, V. V., & Andrushchenko, I. V. (2021) · Radiation Diagnostics Radiation Therapy · doi:10.37336/2707-0700-2021-1-2 · Cited by 2
Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial
Sun, Y., Chen, G., Chen, S., Wang, Y., Hu, Y., & Zhao, Y. (2022) · Trials · doi:10.1186/s13063-022-06393-8 · Cited by 2
Cystic fibrosis with liver involvement in adults has a benign course. Results from a tertiary referral centre cohort
Martínez-Lázaro, A. M., Moreno, R. M. G., Seoane, F. C., Cano-Valderrama, Ó., & Garcı́a-Buey, L. (2022) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2022.9289/2022 · Cited by 2
Ultrasound-Based Diagnostic Methods: Possible Use in Fatty Liver Disease Area
Hari, A. (2022) · Diagnostics · doi:10.3390/diagnostics12112822 · Cited by 2
Association between severe hepatic steatosis examined by Fibroscan and the risk of high-risk colorectal neoplasia
Kim, K. W., Kang, H. W., Yoo, H., Jun, Y., Lee, H. J., Im, J. P., Kim, J. W., Kim, J. S., Koh, S., & Jung, Y. J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279242 · Cited by 2
Psoriasis and steatotic liver disease: Are PNPLA3 and TM6SF2 polymorphisms suitable for the hepato-dermal axis hypothesis?
Agoglia, L., Cardoso, A. C., Barbosa, L., Victer, C. S. X. L., Carneiro, S. C. D. S., de França, P. H. C., Chindamo, M. C., & Villela‐Nogueira, C. A. (2024) · Annals of Hepatology · doi:10.1016/j.aohep.2024.101477 · Cited by 2
Self-citation
Steatosis Assessment with Controlled Attenuation Parameter (CAP) in Various Diseases
Wernberg, C. W., Hugger, M. B., & Thiele, M. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-40542-7_38 · Cited by 2
Liver Stiffness in Alcoholic Liver Disease
Mueller, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-40542-7_11 · Cited by 2
Consenso Mexicano de hepatitis alcohólica
Velasco, J. A. V.-R., la Tijera, F. H., Castro‐Narro, G., Zamarripa-Dorsey, F., Abdo-Francis, J. M., Haddad, I. A., Ledesma, J. M. A., Bielsa-Fernández, M. V., Reyes, E. C., Cisneros-Garza, L. E., et al. (2020) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2020.04.002 · Cited by 2
Noninvasive, quantitative evaluation of hepatic steatosis of donor livers by reference frequency method: A preliminary study
Jin, J., Gong, P., Yang, Q., Hui, D., Zhang, H., Qiu, C., Wang, N., Yi, S., Zheng, R., Yang, Y., et al. (2021) · European Journal of Radiology · doi:10.1016/j.ejrad.2021.109909 · Cited by 2
Comment on Parente et al. The Relationship Between Body Fat Distribution and Nonalcoholic Fatty Liver in Adults With Type 1 Diabetes. Diabetes Care 2021;44:1706–1713
de Vries, M., Kaasjager, K. A. H., & de Valk, H. W. (2021) · Diabetes Care · doi:10.2337/dc21-1773 · Cited by 2
Reconsiderations for the liver donation from a living donor: addressing hepatic steatosis with weight loss preconditioning
Imamura, H., Sano, K., & Saiura, A. (2024) · Hepatology International · doi:10.1007/s12072-024-10693-3 · Cited by 2
Intermittent fasting versus continuous energy restriction in MASLD: a systematic review and meta-analysis
Li, H., & Li, T. (2026) · Frontiers in nutrition · doi:10.3389/fnut.2026.1833688 · Cited by 1
“In individuals with obesity or more advanced steatosis, CAP measurements may be less reliable due to increased signal attenuation and technical limitations, whereas MRI-PDFF is less affected by these factors and maintains higher precision (31, 32).”
Detectability of Liver Steatosis and Fibrosis with Transient Elastography and Controlled Attenuation Parameter in Residents of St. Petersburg
Kovyazina, V. P., Raikhelson, K. L., Константиновна, П. М., Владимировна, П. Е., Palgova, L. K., & Александровна, К. Э. (2021) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2021-31-1-31-38 · Cited by 1
Elastography in Liver-Transplanted Patients
Rigamonti, C., Benedittis, C. D., & Donato, M. F. (2021) · Springer eBooks · doi:10.1007/978-3-030-74132-7_6 · Cited by 1
Quantification of Portal Vein Vascularization Using an Automated Post-Processing Video Analysis Tool
Blank, V., Heni, M., & Karlas, T. (2023) · Ultrasound International Open · doi:10.1055/a-1999-7818 · Cited by 1
Self-citation
Fibrosis Screening of Alcohol-Related Liver Disease Based on Elastography
Mueller, S., & Sporea, I. (2023) · Springer eBooks · doi:10.1007/978-3-031-32483-3_42 · Cited by 1
Comparation between Fibroscan and Hepatus for detecting NAFLD in patients with metabolic dysregulation
Sun, J.-H., Zhang, P.-P., Wang, K., Xu, M., Sun, J., & Li, L. (2024) · The Indonesian Journal of Gastroenterology Hepatology and Digestive Endoscopy · doi:10.24871/251202411-20 · Cited by 1
Rapid appraisal of liver diseases using transient elastography, abdominal ultrasound, and microbiology in Côte d’Ivoire: A single-center study
Leibenguth, M. T., Coulibaly, J. T., Silué, K. D., N’Gbesso, Y. K., Wahed, A. A. E., Utzinger, J., Becker, S. L., & Schneitler, S. (2024) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0012262 · Cited by 1
Noninvasive Tests in Assessment of Patients with Alcohol-Associated Liver Disease
Sanchez, L. O., & Moreno, C. (2024) · Clinics in Liver Disease · doi:10.1016/j.cld.2024.06.010 · Cited by 1
Novel Therapies for Nonalcoholic Steatohepatitis (NASH) and Cardiovascular Risk Reduction
Biswas, T., Lehker, A., & Mukherjee, D. (2024) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x345190241113103911 · Cited by 1
An epidemiological study on the factors including genetic polymorphism influencing ALT > 30 U /L and liver fibrosis progression in metabolic dysfunction‐associated steatotic liver disease among the general population
Sato, S., Iino, C., Sasada, T., Soma, G., Furusawa, K., Yoshida, K., Sawada, K., Mikami, T., Fukuda, S., Nakaji, S., et al. (2024) · JGH Open · doi:10.1002/jgh3.70043 · Cited by 1
Prevalence and Associated Factors of Non-Alcoholic Fatty Liver Disease in People Living with HIV-1
Karatas, F. N., Keklikkıran, Ç., Yilmaz, Y. N., Ay, P., Korten, V., & Sili, U. (2025) · Current HIV Research · doi:10.2174/011570162x340918250312040500 · Cited by 1
FibroScan-AST Score vs Liver Stiffness for the Prediction of Liver Events After HCV Cure
Corma‐Gómez, A., Corona‐Mata, D., Carmona, J. M., Galindo, M. J., Camacho, Á., Martín‐Sierra, C., Gallo-Marín, M., Rincón, P., Valero, I., Pérez-García, M., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae628 · Cited by 1
Possible link between steatotic liver diseases, severe COVID-19 and cognitive impairment in post-COVID-19 syndrome
Reuken, P. A., Wagner, F., Finke, K., Lemhöfer, C., Puta, C., Stengel, S., Scherag, A., Lewejohann, J.-C., Stallmach, A., & Quickert, S. (2025) · Infection · doi:10.1007/s15010-025-02531-x · Cited by 1
The Brazilian traditional dietary pattern was associated with a lower risk of advanced steatosis in patients with metabolic dysfunction-associated steatotic liver disease
Salarini, J. S., Barroso, L. N., Freitas, J. V., Leite, N. C., de Paula, T. P., Padilha, P. D. C., & Peres, W. A. F. (2025) · Nutrition Research · doi:10.1016/j.nutres.2025.04.012 · Cited by 2
Evaluation of Insulin Resistance Markers for Diagnosing Moderate to Severe Hepatic Steatosis in Patients With Human Immunodeficiency Virus Using Transient Elastography
Báguena, C., Tomás, C., Muñoz, Á., Alcaraz, A., Martínez, M. I., Martínez-Rodríguez, R., García-Villalba, E., & Bernal, E. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf324 · Cited by 1
Interplatform Agreement Between Liver Steatosis Analysis and Ultrasound-Guided Attenuation Parameter in the Evaluation of Hepatic Steatosis
Chen, J., Hao, Y., Zhang, Y.-J., Liu, J., Liang, P., & Liu, L. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s528289 · Cited by 1
The diagnostic value of controlled attenuation parameter (CAP) and magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) for the evaluation of intestinal failure-associated liver steatosis among adult chronic intestinal failure patients
Huijbers, A., Korzilius, J. W., Gillis, V. E. L. M., van der Graaf, M., & Wanten, G. J. A. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.08.016 · Cited by 1
Characterizing plasma lipid species in metabolic dysfunction associated steatotic liver disease in persons with type 1 diabetes
Taiwo, A., Thakkar, H., Maschek, J. A., Cox, J. E., Summers, S. A., Jalal, D. I., Dokun, A. O., Sivitz, W. I., & Chaurasia, B. (2025) · Scientific Reports · doi:10.1038/s41598-025-15778-z · Cited by 1
Metabolic Divergence Between MASLD and Metabolic Syndrome: Distinct Clinical Phenotypes and Risk Stratification Implications
Ramírez-Mejía, M. M., Barbalho, S. M., Ponciano‐Rodríguez, G., Eslam, M., George, J., Zheng, M., & Méndez‐Sánchez, N. (2025) · Liver International · doi:10.1111/liv.70305 · Cited by 1
The impact of cART on hepatic steatosis and fibrosis in treatment-naïve PLwHIV: A prospective cohort study
Özdemir, M. Ş., Özdemir, Y. E., Dogdas, A., Nuriyev, K., Şenkal, İ. V., Gündüz, A., Zerdali, E. Y., Kaymakoğlu, S., Mete, B., & Tabak, F. (2025) · International Journal of STD & AIDS · doi:10.1177/09564624251382627 · Cited by 1
Long-term liver stiffness dynamics after sustained virological response in patients with HIV/HCV co-infection and advanced fibrosis
Carmona, J. M., Corona‐Mata, D., Téllez, F., Lorite, M. N. N., Barroso, I., Alados, J. C., Muñoz, R. P., Santos, I. D. L., Vera, F. J., Imaz, A., et al. (2025) · AIDS · doi:10.1097/qad.0000000000004357 · Cited by 1
Association of serum osmolality with metabolic dysfunction-associated steatotic liver disease in adults
Peng, L., & Ai, M. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04309-9 · Cited by 1
Eucalyptus Leaf Extract With Oenothein B Reduces Sugar‐Induced Hepatic and Visceral Fat in Adult Japanese Men: A Randomized Study
Sugimoto, K., Fujisawa, H., Nakagawa, K., Namba, T., Ebihara, S., Kakinuma, T., Yamanouchi, T., & Tokuhara, D. (2025) · Hepatology Research · doi:10.1111/hepr.70058 · Cited by 1
Associations Between Inflammatory Adipokines, Liver Steatosis, and Fibrosis in Patients with Different Degrees of Adiposity with or Without Metabolic Syndrome
Lopes, K. G., de Souza, M. D. G. C., Lopes, F. D. A. M., da Silva, V. L., Terra, C., Carvalho, A. T. P., Bouskela, E., & Kraemer‐Aguiar, L. G. (2025) · Hormone and Metabolic Research · doi:10.1055/a-2712-8064 · Cited by 1
Diagnostic performance of ultrasound-derived fat fraction for assessing steatotic liver disease with histopathology as the reference
Huang, Y., Sun, C., Xu, X., Wang, Y., Wei, L., Cao, J., Qiu, Y., Cheng, J., Wang, S., Cheng, R., et al. (2025) · ULTRASONOGRAPHY · doi:10.14366/usg.25160 · Cited by 1
Self-citation
MASLD: Lipotoxicity and Imaging Parallels from Liver Steatosis to Kidney Injury
Săndulescu, S. M., Ghiga, D. Ș., Tudoraşcu, D. R., Săndulescu, L., Mită, A., Urhuț, M. C., & Taisescu, C. I. (2025) · Life · doi:10.3390/life15121805 · Cited by 3
A predictive model for depression risk in individuals with metabolic dysfunction-associated steatotic liver disease: evidence from NHANES 2017–2023
Qian, H., Song, S., Zhang, Z., Yuan, Y., & Zhang, L. (2025) · Psychology Health & Medicine · doi:10.1080/13548506.2025.2591861 · Cited by 1
Association between serum vitamin D levels and metabolic dysfunction-associated steatotic liver disease: a cross-sectional study based on NHANES 2021–2023
Zhou, S., Xiao, Y., Zhang, D., Yang, S. T., Chen, Y., & Sun, W. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004048 · Cited by 1
Malnutrition Is Associated with Increased Liver Stiffness in Type 2 Diabetes: The Mediating Role of Inflammation
Buglio, A. L., Bellanti, F., Villani, R., Capurso, C. A., Magnati, G. P., Cioffi, S., Tedesco, G., Torsello, C. A., Vendemiale, G., & Serviddio, G. (2025) · Biomolecules · doi:10.3390/biom15121735 · Cited by 1
Use of FibroScan-AST (FAST) Score and Fibrosis-4 Index to Identify Advanced Liver Fibrosis in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
Alsaid, A. H., Argan, R. A., Elamin, Y., Alshiekh, N., Hassan, A., Alotaibi, A. K., Gaarour, I., & Ismail, M. H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010050 · Cited by 1
Effect of region of interest settings on diagnostic performance of attenuation imaging in hepatic steatosis
Tanaka, S., Ohba, N., Saito, N., Tanaka, K., Ishimoto, Y., Ochi, K., Yasui, K., Fujita, M., Abe, K., & Takahashi, S. (2026) · Journal of Medical Ultrasonics · doi:10.1007/s10396-025-01612-6 · Cited by 1
hs-CRP as a Marker of Systemic Low-Grade Inflammation Is Not Associated with Steatotic Liver Disease in Adolescents: Insights from the EVA4YOU Study
Nairz, J., Messner, A., Zollner-Kiechl, S., Kiechl‐Kohlendorfer, U., & Knoflach, M. (2026) · Metabolites · doi:10.3390/metabo16020108 · Cited by 1
Analysis of Visfatin Concentration and Other Potential Biomarkers Associated with MASLD Development in Saliva and Serum of Patients with Obesity—A Pilot Study
Zyśk, B., Smarkusz-Zarzecka, J., Cwalina, U., Gornowicz, A., Orywal, K., Bielawska, A., Mroczko, B., & Ostrowska, L. (2026) · Nutrients · doi:10.3390/nu18040652 · Cited by 1
Abdominal Obesity, Hepatic Steatosis, Oxidative Stress and Diastolic Dysfunction in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
Colangeli, L., Milani, I., Parrotta, M. E., Longo, S., Nucera, A., Federici, M., Palleschi, S., Rossi, B., Mantovani, A., Muscoli, S., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041968 · Cited by 1
Metabolic determinants of hepatocellular carcinoma after SVR: persisting uncertainties
Bhanushali, M., Bhagat, N., De, A., & Duseja, A. K. (2026) · Gut · doi:10.1136/gutjnl-2026-338377 · Cited by 1
Ultrasound-derived Fat Fraction for Pre-operative Prediction and Monitoring of Hepatic Steatosis Normalization After Metabolic Surgery in Patients With Obesity
Hu, D., Yang, H., Yu, G., Wei, L., Liu, Y., Zhou, H. K., Cai, W., Wen, H., Li, G., Wu, S., et al. (2026) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2026.02.002 · Cited by 1
The association of TyG-BMI with MAFLD and liver fibrosis: a cross-sectional study
Wang, X., Han, X., Liu, J., & Qi, Y. (2026) · Scientific Reports · doi:10.1038/s41598-026-46378-0 · Cited by 1
Comparative diagnostic performance of ultrasound-guided attenuation parameter versus B-mode scoring for hepatic steatosis assessment: an ordinal-scale statistical approach
Kumada, T., Toyoda, H., Ogawa, S., Gotoh, T., Suzuki, Y., Imajo, K., Yoneda, M., Sugimoto, K., Kuroda, H., Tamaki, N., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02403-7 · Cited by 1
Liver Fibrosis Screening in Childhood Acute Lymphoblastic Leukemia Survivors by Transient Elastography: A Case-Control Study
Khera, S., Prasad, A. S., & Kapoor, R. (2026) · Indian Pediatrics · doi:10.1007/s13312-026-00342-3 · Cited by 1
Predictors of Discordance Between Controlled Attenuation Parameter and Magnetic Resonance-Proton Density Fat Fraction in Hepatic Steatosis
Kim, D. Y., Rhee, H.-J., & Kim, B. R. (2026) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000001042 · Cited by 1
Optimized CAP cut-offs for metabolic dysfunction associated steatotic liver disease in patients living with obesity: a large biopsy-based prospective study
Soliman, R., Elbasiony, M., Helmy, A. F., Mikhail, N. N. H., Ezzat, H., Gad, A. M., Abdelhalim, E., Zalata, K. R., Masoud, R., hassan, A., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-47209-y · Cited by 1
Association between the uric acid-to-HDL-cholesterol ratio and diabetic kidney disease in individuals with type 2 diabetes and NAFLD: evidence from NHANES and an external hospital cohort
Gong, Z., Zhang, D., Cai, N., & Wang, P. (2026) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2026.2663523 · Cited by 1
Saroglitazar for non-obese metabolic-dysfunction associated steatotic liver disease (MASLD): An open-label randomised controlled trial
Bhagat, N., De, A., Duseja, A. K., Ganesh, C. P., Kumar, M., Mehta, M., Taneja, S., Sahni, N., & Singh, V. (2026) · The Indian Journal of Medical Research · doi:10.25259/ijmr_2953_2025 · Cited by 1
Self-citation
Association between triglyceride-glucose-related indices and the prevalence of MAFLD/MASLD and hepatic fibrosis in American adults: an analysis of NHANES data
Yong, J., Wang, H., Liu, L., Zhao, H., Sun, C. J., Wang, S., Luo, P., Xia, Y., & Ding, B. W. (2026) · Critical Public Health · doi:10.1080/09581596.2026.2664251 · Cited by 1
Reliability of Hepatic Steatosis Quantification by Controlled Attenuation Parameter in Steatotic Liver Disease
Simonis, L., Marcour, Y., Embacher, J., Hruska, P., Andersen, P. J., Mehl, B., Balcar, L., Jachs, M., Trauner, M. A., Krag, A. A., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.05.006 · Cited by 1
Concomitant Liver Steatosis in Chronic Hepatitis B Virus Infection Is Linked to a Distinct Cytokine Profile and Reduced Viral Load
John, K., Voss, M.-L., Aoua, S. A., Franck, M., Falk, C. S., Wedemeyer, H. H., Schulze‐Osthoff, K., & Bantel, H. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag281 · Cited by 1
Increased Liver Stiffness Despite Biochemical Recovery in Living Donors 1‐Year Post‐Hepatectomy
Gwon, S. M., Chi, S., Baik, J., Do, H., Kwon, J. H., Park, H., Lee, I., Choi, Y. S., Jung, K. S., Park, S., et al. (2026) · Liver International · doi:10.1111/liv.70744 · Cited by 1
Self-citation
Acceptability of Brazzein-Sweetened Ice Cream as a Sugar-Reduction Strategy in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Double-Blind Randomized Crossover Sensory Study
Va, I., Goncharov, A. А., Pilipenko, V. I., Нисановна, С. А., Kochetkova, A. A., & Bessonov, V. V. (2026) · Dairy · doi:10.3390/dairy7030044 · Cited by 1
Fasting insulin to HDL-C ratio is correlated with MASLD severity in Chinese overweight/obesity: a cross-sectional analysis
Xu, X., Wang, X., Yu, L., Yang, X., Wang, P., Wang, Y., Guan, Z., Chunjun, L. I., & Han, T. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02424-6 · Cited by 1
Medical therapy of MASLD – consequences of the paradigm shift from histology to non-invasive tests
Messer, E. K., Petroff, D., Sugimoto, K., Newsome, P. N., Moriyasu, F., Shalimar, Burgio, M. D., Voican, C. S., Vilgrain, V., de Lédinghen, V., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101996 · Cited by 1
Self-citation
A cohort study of physical activity, gut microbiota, serum metabolites, and the risk of steatotic liver disease
Liang, S., Shao, Y., Qin, H., Li, M., Xu, H., Zhang, J., Sun, Z., Cao, H., Qin, X., Zhang, Z., et al. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102443 · Cited by 1
Prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the CHESS-LiverHealth project): cross-sectional baseline data from a prospective cohort study
Liu, S., Liu, X., Song, J., Zhang, Y., Shi, H., Huang, E., Ma, L., Qi, Y., Bu, Y., Liu, R., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00224-4 · Cited by 1
Self-citation
The evaluation of the repeatability of the 13C-ketoisocaproate breath test for assessing hepatic mitochondrial function
Afolabi, P. R., Scorletti, E., Calder, P. C., & Byrne, C. D. (2019) · Isotopes in Environmental and Health Studies · doi:10.1080/10256016.2019.1588265 · Cited by 1
Practical Use of Transient Elastography in Screening for Nonalcoholic Steatohepatitis in a Japanese Population
Hirono, H., Watanabe, K., Hasegawa, K., & Ohkoshi, S. (2019) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2018.00048 · Cited by 1
Noninvasive Diagnostic Approach to NASH: Radiological Diagnostics
Tincopa, M. A., & Harrison, S. A. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_14 · Cited by 1
IV. Evaluation of Liver Fibrosis and Steatosis in Non-alcoholic Fatty Liver Disease
Tamaki, N., & Kurosaki, M. (2020) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.109.34 · Cited by 1
Complete alcohol abstinence increases the risk of NAFLD but not severity. A population analysis with transient elastography
Xiao, J., Ng, C. H., Chan, K. E., Tang, A. S. P., Teh, R., Ling, A. H. Z., Yong, J. N., Lim, W. H., Tan, D. J. H., Tan, C., et al. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2022.2105168 · Cited by 1
Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection
Liu, C., Jiang, W., Wu, D., Zeng, Q., Wang, Y., & Tang, H. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07695-2 · Cited by 1
Diagnostic Performance of Greyscale Ultrasound in Detecting Fatty Liver Disease in a Type 2 Diabetes Population Using FibroScan as the Reference Standard
Wiafe, Y. A., Anyitey-Kokor, I. C., Nmai, R. A., Afihene, M., & Roberts, L. R. (2023) · Cureus · doi:10.7759/cureus.40756 · Cited by 1
The Role of ElastPQ in Assessing Liver Stiffness for Non-Alcoholic Fatty Liver Disease in Patients Treated with Atypical Antipsychotic Drugs
Sun, L., Li, N., Zhang, L., & Chen, J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s409210 · Cited by 1
Praxisorientierte Strategien für Screening, Diagnostik und Therapie der NAFLD
Kreimeyer, H., Manka, P. P., & Canbay, A. E. (2023) · Gastro-News · doi:10.1007/s15036-023-3265-4 · Cited by 1
Lack of associations of microRNAs with severe NAFLD in people living with HIV: discovery case-control study
Frías, M., Corona‐Mata, D., Moyano, J. M., Espejo, Á. C., López‐López, P., Caballero‐Gómez, J., Ruiz-Cáceres, I., Casares-Jiménez, M., Valero, I., Rivero‐Juárez, A., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1230046 · Cited by 1
Disease specific imaging utilizing support vector machine: assessment of steatosis
Baek, J., Basavarajappa, L., Hoyt, K., & Parker, K. J. (2023) · IEEE International Ultrasonics Symposium · doi:10.1109/ius51837.2023.10307150 · Cited by 1
Improvement of carotid atherosclerosis and peripheral artery disease after hepatitis C virus eradication by direct-acting antivirals
Cuciureanu, T., Stanciu, C., Năstasă, R., Stratina, E., Minea, H. O., Zenovia, S., Sfarti, C. V., Muzica, C. M., Huiban, L., Stafie, R., et al. (2024) · Romanian Journal of Morphology and Embryology · doi:10.47162/rjme.64.4.04 · Cited by 1
Epidemiology of Metabolic Dysfunction-Associated Fatty Liver Disease in Type 2 Diabetes Mellitus and Effects of Antiglycemic Therapy on Liver Fibrosis: A Retrospective Study
Butt, M. I., Puri, G., Berkman, K., Ryder, S. J., Knowles, J., Shahzad, M. A., Malik, M. A., Shalev, N., & Sexton, J. (2024) · Journal of Endocrinology and Metabolism · doi:10.14740/jem937 · Cited by 1
Evaluación comparativa de APRI, FIB-4, HFS y NFS: herramientas de puntuación para la fibrosis hepática en la población mexicana con MASLD
Priego-Parra, B. A., Triana‐Romero, A., Bernal-Reyes, R., Icaza-Chávez, M. E., Vázquez, S., Amieva‐Balmori, M., Cano-Contreras, A. D., Vivanco-Cid, H., & Remes-Troche, J. M. (2024) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2024.03.001 · Cited by 1

Authors: Karlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., Ferraioli, G., Chan, W.-K., Wong, V. W.-S., Myers, R. P., Chayama, K., Friedrich-Rust, M., Beaugrand, M., Shen, F., Hiriart, J.-B., Sarin, S. K., Badea, R., Jung, K. S., Marcellin, P., Filice, C., Mahadeva, S., Wong, G. L.-H., Crotty, P., Masaki, K., Bojunga, J., Bedossa, P., Keim, V., & Wiegand, J.
Affiliations: University Hospital Leipzig (DE)
IFB Adiposity Diseases (DE)
Echosens (France) (FR)
Shanghai Jiao Tong University (CN)
Institute of Liver and Biliary Sciences (IN)
Yonsei University (KR)
Inserm (FR)
University of Pavia (IT)
University of Malaya (MY)
Chinese University of Hong Kong (HK)
University of Calgary (CA)
Hiroshima University Hospital (JP)
Hôpital Jean-Verdier (FR)
Centre Hospitalier Universitaire de Bordeaux (FR)
Iuliu Hațieganu University of Medicine and Pharmacy (RO)
University Hospital Frankfurt (DE)
Corresponding author: Wiegand, Johannes
ORCID: Karlas, Thomas
Petroff, David
Sasso, Magali
Fan, Jian-Gao
Kumar, Manoj
Han, Kwang-Hyub
Cardoso, Ana C.
Ferraioli, Giovanna
Chan, Wah-Kheong
Wong, Vincent Wai-Sun
Chayama, Kazuaki
Shen, Feng
Hiriart, Jean-Baptiste
Sarin, Shiv K.
Badea, Radu
Marcellin, Patrick
Mahadeva, Sanjiv
Wong, Grace Lai-Hung
Crotty, Pam
Bojunga, Joerg
Wiegand, Johannes
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2017-05
Volume: 66
Issue: 5
Pages: 1022-1030
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2016.12.022
OpenAlex: W2564467149
Cited by: 1,275
References: 65
Citations by year: 2026: 164 · 2025: 185 · 2024: 180 · 2023: 139 · 2022: 161 · 2021: 150 · 2020: 117 · 2019: 77 · 2018: 67 · 2017: 31
FWCI: 7.94
Type: journal article
Language: en
Open access: green
www.sciencedirect.com
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Ultrasound Imaging and Elastography
Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Ultrasound in Clinical Applications
Keywords: controlled attenuation parameter, hepatic steatosis, vibration-controlled transient elastography, FibroScan, chronic liver disease, diabetes mellitus, body mass index, liver ultrasound, receiver operating characteristic
MeSH terms: Adult, Fatty Liver, Female, Humans, Male, Middle Aged, ROC Curve, Ultrasonography, Meta-Analysis as Topic, Body Mass Index, Hepatocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks